Article Listing - Caraco wins generic Ultracet appeal
Brazilian pharma exports to GCC up 73% to reach over $7.4 million in 2012
13 May 2013
Brazil exported $7.48 million worth of pharmaceutical products to the Gulf Cooperation Council (GCC) region in 2012, increasing by over 73% compared to $4.31 million in 2011, according to figures released by the Arab Brazilian Chamber of Commerce (ABCC). The Kingdom of Saudi Arabia and the United Arab Emirates (UAE) accounted for the biggest share of the Brazilian pharmaceutical exports at 57.02% and 41.61%, respectively.
NovaBay Pharmaceuticals: tuning in for a crescendo of data, say analysts
13 May 2013
US biotech firm NovaBay Pharmaceutical's (Nasdaq: NBY) first-quarter 2013 results set the scene for a potentially transformational second half of 2013, with results expected from three Phase II studies of its topical anti-infective, auriclosene (NVC-422), comment analysts at Edison Investment Research.
Elan pays $1 billion for a 21% share of Theravance royalties on four respiratory programs
13 May 2013
US biotech firm Theravance (Nasdaq: THRX) has entered into a royalty participation agreement wherein Ireland-based Elan (NYSE: ELN) will purchase a participation interest in potential future royalty payments related to four respiratory programs partnered with UK pharma giant GlaxoSmithKline (LSE: GSK).
Vectura sets up JV, Kinnovata, for new respiratory business in China
13 May 2013
UK-based developer of inhaled therapies Vectura (LSE: VEC) saw its shares rise 4.8% to 96.93 pence in morning trading (May 13), after it revealed that it has established Tianjin Kinnovata Pharmaceutical Company in China with two partners; Tianjin KingYork Group Company, a leading Chinese pharmaceutical company and specialist manufacturer of corticosteroid based products, and Zendex Bio Strategy, a private equity investor based in Hong Kong.
Third milestone for Neovacs in the Tracker program for rheumatoid arthritis
13 May 2013
French biotech firm Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, has received 414,839 euros ($538,129) from the French Innovation agency Oseo following achievement of a third milestone in early April, under the schedule agreed between the parties as part of the Tracker Project in rheumatoid arthritis (RA).
Africa's pharmaceutical industry faces numerous challenges, VoA reports
13 May 2013
Providing Africans with affordable health care could be realized if pharmaceutical products were produced on the African continent, writes Marthe van der Wolf for Voice of America. The continent faces many challenges before it will be able produce its own medicines.
FDA approves Theravance and GSK's Breo Ellipta to treat COPD
13 May 2013
The US Food and Drug Administration on Friday (May 10) approved Breo Ellipta (fluticasone furoate, an inhaled corticosteroid, and vilanterol inhalation powder, a long-acting beta2-adrenergic agonist), from UK pharma giant GlaxoSmithKline (LSE: GSK) and US biotech firm Theravance (Nasdaq: THRX).
Actavis and Warner Chilcott leap on merger talks; possible bid for Adcock Ingram
13 May 2013
US generics major Actavis NYSE: ACT) confirmed on Friday (May 10) that it has entered into early stage discussions with Ireland-based Warner Chilcott (Nasdaq: WCRX) regarding a potential combination of the two companies. Actavis further stated that no agreement has been reached and it does not intend to issue further comment regarding its business development initiatives. A similar statement was issued by Warner Chilcott.
US FDA to allow generic copies of Endo's Opana
13 May 2013
Endo Health Solutions (Nasdaq: ENDP) announced Friday (May 10) that the US Food and Drug Administration has denied a Citizen Petition filed by its subsidiary, Endo Pharmaceuticals, regarding the potential approval of additional non-abuse deterrent formulations of generic oxymorphone, the active ingredient of its Opana. Endo's shares fell 5.3% to $34.97 on the news.
Lilly drops enzastaurin development; Remoxy future viewed by Pfizer and partners
10 May 2013
US drug major Eli Lilly (NYSE: LLY) revealed that Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL), failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy.
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
